Last update 19 Sep 2024
ThisCART 19(Fundamenta Therapeutics,)
Last update 19 Sep 2024
Overview
Basic Info
Drug Type Universal CAR-T |
Synonyms THISCART-19 |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Related
7
Clinical Trials associated with ThisCART 19(Fundamenta Therapeutics,)A Single Dose-escalation and Dose-expansion Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma.
A Single-center, Dose Selection Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Auto-CAR T Relapsed B-cell Non-Hodgkin's Lymphoma
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Allogeneic Anti CD19 CAR-T Bridging to Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia
100 Clinical Results associated with ThisCART 19(Fundamenta Therapeutics,)
Login to view more data
100 Translational Medicine associated with ThisCART 19(Fundamenta Therapeutics,)
Login to view more data
100 Patents (Medical) associated with ThisCART 19(Fundamenta Therapeutics,)
Login to view more data
100 Deals associated with ThisCART 19(Fundamenta Therapeutics,)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Lymphoma | Phase 2 | CN | 01 May 2023 | |
| B-cell lymphoma recurrent | Phase 1 | CN | 01 Dec 2022 | |
| Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | CN | 01 Dec 2022 | |
| Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | CN | 01 Dec 2022 | |
| Recurrent Non-Hodgkin Lymphoma | Phase 1 | CN | 01 Dec 2022 | |
| Refractory B Acute Lymphoblastic Leukemia | Phase 1 | - | 15 Oct 2022 | |
| B-cell lymphoma refractory | Phase 1 | CN | 25 Oct 2021 | |
| B-Cell Malignant Neoplasm | Phase 1 | CN | 25 Oct 2021 | |
| B-Cell Leukemia | Discovery | CN | 09 May 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04384393 (ASGCT2024) Manual  | Phase 1 | 2 | (fndaprazyf) = not observed wlfkafsffl (xnxxyizatv ) View more | Positive | 07 May 2024 | ||
NCT04384393 (EHA2022) Manual | Phase 1 | CD19 positive Non-Hodgkin Lymphoma CD19 Positive | 8 | Fludarabine Phosphate+Cyclophosphamide+ThisCART 19 | (bputamkgfm) = thxcbgrsoa cilzdbxqrc (qjgshdhtbk ) View more | Positive | 12 May 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free